Abstract

This article narrates the development and promotion in the 1950s and 1960s of Merck, Sharp & Dohme's Diuril (chlorothiazide), an antihypertensive drug, which played a significant role in the redefinition of high blood pressure as a widespread target for chronic pharmaceutical consumption. The joined careers of Diuril and hypertension in the late twentieth century demonstrate the connections between the clinical research, clinical practice, and marketing practices through which pharmaceuticals and disease categories come to define one another. By examining a series of internal documents preserved in the Merck Archives alongside a careful reading of the clinical literature and industry journals of the time, this article explores how the ambitions of marketers, physicians, and public health advocates found convergence in the expanding pharmaceutical prevention of chronic diseases.

pdf

Additional Information

ISSN
1086-3176
Print ISSN
0007-5140
Pages
pp. 749-794
Launched on MUSE
2005-12-01
Open Access
No
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.